ESMO Media Releases
ESMO 2012 Press Release: New weapons in the fight against cancer
Where are the most promising developments from first-in-human studies?
Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer
Head-to-head study compares of crizotinib with standard chemotherapy in this patient group
Phase III data in treatment of renal cell carcinoma reported
New trial results on pazopanib and temsirolimus have important implications for patients
Should aspirin be used to prevent cancer?
Debate at ESMO 2012 Congress focuses on whether there is enough evidence to start using aspirin to reduce the risk of colorectal cancer
First large scale trial of whole-genome cancer testing for clinical decision-making reported
Study opens a new door to more personalised treatment of advanced breast cancer
New findings highlight the challenges of managing blood clotting in cancer patients
New findings highlight the challenges of managing blood clotting in cancer patients
New findings on optimal duration of trastuzumab therapy for women
Long awaited results constitute a further milestone
Studies show advances in gastrointestinal cancer treatments
Phase III data reported at ESMO 2012
Equal access to cancer care is a medical and ethical imperative
ESMO Press statement - European Commission proposal would streamline patient access to medicines
ESMO welcomes the recent EC proposal which will facilitate patient access to innovative treatments on an EU-wide level